Oncotarget

Research Papers:

HistoneH3 demethylase JMJD2A promotes growth of liver cancer cells through up-regulating miR372

Jiahui An, Jie Xu, Jiao Li, Song Jia, Xiaonan Li, Yanan Lu, Yuxin Yang, Zhuojia Lin, Xiaoru Xin, Mengying Wu, Qidi Zheng, Hu Pu, Xin Gui, Tianming Li and Dongdong Lu _

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2017; 8:49093-49109. https://doi.org/10.18632/oncotarget.17095

Metrics: PDF 2000 views  |   HTML 1757 views  |   ?  


Abstract

Jiahui An1, Jie Xu1, Jiao Li2, Song Jia2, Xiaonan Li1, Yanan Lu1,Yuxin Yang1, Zhuojia Lin1, Xiaoru Xin1, Mengying Wu1, Qidi Zheng1, Hu Pu1, Xin Gui1, Tianming Li1 and Dongdong Lu1

1School of Life Science and Technology, Tongji University, Shanghai, 20092, China

2School of Medicine, Tongji University, Shanghai, 200092, China

Correspondence to:

Dongdong Lu, email: ludongdong@tongji.edu.cn

Keywords: liver cancer, HistoneH3 demethylase JMJD2A, miR372, P21WAF1/Cip1, Pim1

Received: October 07, 2016     Accepted: April 01, 2017     Published: April 13, 2017

ABSTRACT

Changes in histone lysine methylation status have been observed during cancer formation. JMJD2A protein is a demethylase that is overexpressed in several tumors. Herein, our results demonstrate that JMJD2A accelerates malignant progression of liver cancer cells in vitro and in vivo. Mechanistically, JMJD2A promoted the expression and mature of pre-miR372 epigenetically. Notably, miR372 blocks the editing of 13th exon-introns-14th exon and forms a novel transcript( JMJD2AΔ) of JMJD2A. In particular, JMJD2A inhibited P21(WAF1/Cip1) expression by decreasing H3K9me3 dependent on JMJD2AΔ. Thereby, JMJD2A could enhance Pim1 transcription by suppressing P21(WAF1/Cip1). Furthermore, through increasing the expression of Pim1, JMJD2A could facilitate the interaction among pRB, CDK2 and CyclinE which prompts the transcription and translation of oncogenic C-myc. Strikingly, JMJD2A may trigger the demethylation of Pim1. On the other hand, Pim1 knockdown and P21(WAF1/Cip1) overexpression fully abrogated the oncogenic function of JMJD2A. Our observations suggest that JMJD2A promotes liver cancer cell cycle progress through JMJD2A-miR372-JMJD2AΔ-P21WAF1/Cip1-Pim1-pRB-CDK2-CyclinE-C-myc axis. This study elucidates a novel mechanism for JMJD2A in liver cancer cells and suggests that JMJD2A can be used as a novel therapeutic targets of liver cancer.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 17095